Ilaris Articles
More news at EULAR from Novartis, J&S and B-MS
7 June 2012
Novartis gains NIH listing in Japan for Ilaris
23 November 2011
Ph III study shows Novartis’ canakinumab substantially reduces steroid use in children with SJIA
8 November 2011
Novartis and Vectura’s NVA237 filed in Europe; positive Ph III data at ERS; Gilenya, Ilaris approved in Japan
28 September 2011
Novartis’ Ilaris provides substantial symptom relief in 84% of patients with most serious form of childhood arthritis
19 September 2011
US FDA stalls Novartis Ilaris approval for gouty arthritis, calling for more clinical data
31 August 2011
US FDA advisory panel says no to Novartis gout drug Ilaris; agency backs safety of Shire’s Firazyr
22 June 2011
Novartis wins in Apotex patent case; gout drug ACZ885 reduced risk of new attacks by up to 68% vs steroid
26 May 2011
New study highlights changes in the management of gout and hyperuricemia among US rheumatologists and PCPs
2 March 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
EU approves Novartis’ Ilaris for CAPS; AstraZeneca withdraws Zactima marketing applications
28 October 2009
Showing 1-17 of 17 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
